This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Google Scholar Articles by Eliopoulos, H. Articles by Gordon, G. PubMed PubMed Citation Articles by Eliopoulos, H. Articles by Gordon, G. Related Collections Clinical Research Clinical Research: Clinical Trials

Phase 0 Trials: An Industry Perspective

Authors' Affiliations: Abbott Laboratories, Abbott Park, Illinois

Requests for reprints: Gary Gordon, Abbott Laboratories, 200 Abbott Park Road, Department R48K, Building AP30, Third Floor, Abbott Park, IL 60064. Phone: 847-936-0992; Fax: 1-847-937-7812; E-mail: gary.gordon{at}abbott.com.

Abstract

Worldwide, cancer is a leading cause of morbidity and mortality. An increased understanding of the disease and its process has resulted in a multitude of new targeted therapies. The costs as well as time from drug discovery to market, however, remain staggeringly high and protracted, with the majority of compounds never reaching phase III. The concept of an exploratory or phase 0 trial was introduced as a mechanism to enhance and accelerate the overall process of new oncologic drug development. Performance of a phase 0 study allows researchers to better understand the pharmacokinetic and pharmacodynamic properties of compounds in human subjects before initiation of phase I trials. Data gleaned from a phase 0 trial are beneficial not only in prioritizing promising compounds but also in allowing the modification of phase I study design before initiation. To date, few researchers have taken advantage of the potential benefits of phase 0 trials. This review focuses on the purpose as well as the potential merits of phase 0 trials from the perspective of a pharmaceutical company. The review summarizes the experience of a team of researchers with ABT-888, a novel poly (ADP-ribose) polymerase agent that inhibits an enzyme critical for repairing damage to DNA, which is one of the first compounds to be investigated using the phase 0 clinical trial design.

This article has been cited by other articles:

				G. C. Prendergast Translational Research: Speeding New Concepts between Lab and Clinic Cancer Reviews Online Content, July 1, 2008; 2008(7): 13 - 14. [Full Text] [PDF]

				J. H. Doroshow and R. E. Parchment Oncologic Phase 0 Trials Incorporating Clinical Pharmacodynamics: from Concept to Patient Clin. Cancer Res., June 15, 2008; 14(12): 3658 - 3663. [Abstract] [Full Text] [PDF]

				A. H. Calvert and R. Plummer The Development of Phase I Cancer Trial Methodologies: the Use of Pharmacokinetic and Pharmacodynamic End Points Sets the Scene for Phase 0 Cancer Clinical Trials Clin. Cancer Res., June 15, 2008; 14(12): 3664 - 3669. [Abstract] [Full Text] [PDF]

				D. Jacobson-Kram and G. Mills Leveraging Exploratory Investigational New Drug Studies to Accelerate Drug Development Clin. Cancer Res., June 15, 2008; 14(12): 3670 - 3674. [Abstract] [Full Text] [PDF]

				A. J. Murgo, S. Kummar, L. Rubinstein, M. Gutierrez, J. Collins, R. Kinders, R. E. Parchment, J. Ji, S. M. Steinberg, S. X. Yang, et al. Designing Phase 0 Cancer Clinical Trials Clin. Cancer Res., June 15, 2008; 14(12): 3675 - 3682. [Abstract] [Full Text] [PDF]

				M. Gutierrez and D. Collyar Patient Perspectives on Phase 0 Clinical Trials Clin. Cancer Res., June 15, 2008; 14(12): 3689 - 3691. [Full Text] [PDF]